News headlines about Aduro BioTech (NASDAQ:ADRO) have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aduro BioTech earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.5082955010034 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
ADRO has been the topic of a number of research reports. BidaskClub raised Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 23rd. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer initiated coverage on Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, ValuEngine lowered Aduro BioTech from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.71.
Shares of Aduro BioTech (ADRO) traded down $0.05 on Friday, hitting $6.05. The stock had a trading volume of 334,192 shares, compared to its average volume of 511,353. Aduro BioTech has a 1 year low of $5.82 and a 1 year high of $14.05. The stock has a market capitalization of $467.69 and a P/E ratio of -4.45.
COPYRIGHT VIOLATION WARNING: “Aduro BioTech (ADRO) Receives Daily News Impact Score of 0.13” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/18/aduro-biotech-adro-earning-somewhat-positive-media-coverage-analysis-finds.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.